MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Artera

News headline image
New Data Highlight Artera's MMAI Consistency Across Diverse Patient Populations at ASTRO 2026
From Artera
Via Business Wire
News headline image
Artera Enrolls First Patient in DIRECT-AI Registry, Marking Milestone in Real-World Evidence Generation for AI-Powered Prostate Cancer Care
From Artera
Via Business Wire
News headline image
Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC)
From Artera
Via Business Wire
News headline image
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
From Artera
Via Business Wire
News headline image
Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer
From Artera
Via Business Wire
News headline image
Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion
From Artera
Via Business Wire
News headline image
Artera Debuts ArteraAI Prostate Test (Post‑RP), Expanding its Oncology Portfolio
From Artera
Via Business Wire
News headline image
Artera Unveils Data Demonstrating Prognostic and Predictive Utility in Breast Cancer at SABCS 2025
From Artera
Via Business Wire
News headline image
Artera Unveils Four Presentations at ASTRO 2025 Illustrating its Multimodal Artificial Intelligence (MMAI) Platform’s Scalability, Speed, and Potential to Personalize Treatment Decisions for Multiple Cancers
From Artera
Via Business Wire
News headline image
Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care
From Artera
Via Business Wire
News headline image
U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered Software Transforming Prostate Cancer Care
From Artera
Via Business Wire
News headline image
Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test
From Artera
Via Business Wire
News headline image
Artera Achieves Nationwide Access for its ArteraAI Prostate Test with New York State License
From Artera
Via Business Wire
News headline image
The ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer
From Artera
Via Business Wire
News headline image
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
From Artera
Via Business Wire
News headline image
Journal of Clinical Oncology Publishes Significant Evidence in Advancing Racial Equity in Cancer Care Through Artera's Multimodal AI Model
From Artera
Via Business Wire
News headline image
Artera Announces 1st Patient Enrolled in PROSTATE-IQ Trial to Reduce Burden of Hormone Therapy in Men with Prostate Cancer Recurrence After Prostatectomy
From Artera
Via Business Wire
News headline image
Artera Announces Collaboration with Tempus to Expand Access to Personalized Prostate Cancer Treatment
From Artera
Via Business Wire
News headline image
Artera’s Multimodal Artificial Intelligence Named Among TIME's 2024 Best Inventions
From Artera
Via Business Wire
News headline image
Artera Receives California Lab License, Expanding Access to its ArteraAI Prostate Test
From Artera
Via Business Wire
News headline image
Artera Announces Two Presentations at ASTRO 2024 Validating its MMAI Platform to Inform Treatment Decisions for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC)
From Artera
Via Business Wire
News headline image
Artera Announces Expansion of the ArteraAI Prostate Test to Inform Active Surveillance Decisions for Lower Risk Prostate Cancer Patients
From Artera
Via Business Wire
News headline image
Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform
From Artera
Via Business Wire
News headline image
Artera Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI
From Artera
Via Business Wire
News headline image
Artera Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker
From Artera
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story